Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
NCT ID: NCT01176916
Last Updated: 2021-10-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
564 participants
INTERVENTIONAL
2011-02-09
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Aromasin (exemestane)
the dosage, frequency and duration base on the LPD approved by SFDA.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aromasin (exemestane)
the dosage, frequency and duration base on the LPD approved by SFDA.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ER positive.
* The patient must be postmenopausal woman.
* The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will switch to receive Aromasin® treatment (The decision to prescribe Aromasin® will necessarily precede and will be independent of the decision to enroll patients in the study).
Exclusion Criteria
* Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase inhibitors (not Aromasin®).
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department
Bengbu, Anhui, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Second Affiliated hospital of Anhui Medical University
Hefei, Anhui, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
The First hospital of LanZhou university
Lanzhou, Gansu, China
Breast Surgery of The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
SUN YAT-SEN Memorial Hospital , SUN YAT-SEN University
Guangzhou, Guangdong, China
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
Thyroid and breast surgery
Shenzhen, Guangdong, China
Affiliated hospital of Guangdong medical college
Zhanjiang, Guangdong, China
Hainan General Hospital
Haikou, Hainan, China
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
The First Affiliated Hospital of Xinxiang Medical University
Weihui, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Henan provincial people's hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Jingzhou Hospital Tongji Medical College Huazhong university of science and Technology
Jingzhou, Hubei, China
Breast and thyroid surgery of the Central Hospital of WuHan
Wuhan, Hubei, China
Hunan Provincial People's Hospital
Changsha, Hunan, China
Xiangya Hospital Central South University /Department of Breast
Changsha, Hunan, China
The Affiliated Hospital of inner Mongolia medical university
Hohhot, Inner Mongolia, China
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China
Jiangsu Cancer Hospital/ Surgery Department
Nanjing, Jiangsu, China
Jinling Hospital
Nanjing, Jiangsu, China
Jiangsu Province Hospital/ Surgery Department
Nanjing, Jiangsu, China
Nanjing Maternity and Child Health Care Hospital/Department of Breast Surgery
Nanjing, Jiangsu, China
Suzhou Municipal Hospital
Suzhou, Jiangsu, China
The first hospital of jilin university
Changchun, Jilin, China
The Fourth Affiliated Hospital Of China Medical University
Shenyang, Liaoning, China
The First Affiliated Hospital of The Fourth Military Medical University
Xi'an, Shaanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Linyi People's Hospital
Linyi, Shandong, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Qingdao municipal Hospital
Qingdao, Shandong, China
Breast Surgery of The Weifang People's Hospital
Weifang, Shandong, China
Breast Surgery of YanTai Yu Huang Ding Hospital
Yantai, Shandong, China
Breast and thyroid surgery of Central Hospital of Zibo
Zibo, Shandong, China
West China Hospital, Sichuan University/ Oncology Department
Chengdu, Sichuan, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Affiliated Hospital of North Sichuan Medical College
Nanchong, Sichuan, China
Tianjin Cancer Hospital/Breast cancer department
Tianjin, Tianjin Municipality, China
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Cancer Hospital Chinese Academy of medical sciences
Beijing, , China
Fifth Medical Center of the PLA General Hospital
Beijing, , China
Beijing Cancer Hospital
Beijing, , China
Peking University Third Hospital/Department of Oncology
Beijing, , China
China-Japan Friendship Hospital
Beijing, , China
Fudan University Shanghai Cancer center/Department of Breast Surgery
Shanghai, , China
Yangpu District Central Hospital
Shanghai, , China
Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NRA5990043
Identifier Type: OTHER
Identifier Source: secondary_id
A5991093
Identifier Type: -
Identifier Source: org_study_id